PureIMS

Private

RodenHealthcare & Life Scienceshttps://pureims.com/

Last Round

Early Funding

Apr 3, 2023

Company Overview

PureIMS is a therapeutic devices and pharmaceuticals company that develops and commercializes inhaled therapies based on its proprietary Cyclops® dry powder inhaler.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials, Pharma Supply Chain

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

dry powder inhalerDPIpulmonary drug deliverydrug delivery platforminhalation technologydrug-device combinationco-development servicespharmaceutical licensinghigh dose deliveryclinical-stage pharmaceuticalpre-filled inhalersingle-use inhalerParkinson's disease treatmentanaphylaxis treatmentcystic fibrosis treatmentGMP manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PureIMS Comps

Public and private peers based on sector, stage, and business model.

PureIMS comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

PureIMS Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Early Funding	Apr 3, 2023
Early Funding	Apr 26, 2019
Early Funding	Oct 12, 2017

View all Funding Rounds

Key People

Founding team and executive leadership

Jaap Wieling

Chief Executive Officer

Executive Team

PureIMS Investors

Notable investors and investment history

PureIMS investors
Investor	Rounds
Boost-UP Foundation	Early Funding
Carduso Capital	Early Funding

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Feb 17, 2026
Grew 83% QoQ, from 6 to 11 employees.
Jan 19, 2026
Monthly visitors grew 70% MoM, from 866 to 1.5K.

View all signals

PureIMS Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

PureIMS Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PureIMS's valuation, stock price, and market status.

Firmographic Details

HeadquartersRoden

Employee Range12

Year Founded2014

Last FundingApr 3, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.